Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Plasma Cell Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Hematopoietic and Lymphoid Cell Neoplasm
Lymphocytic Neoplasm
B-Cell Neoplasm
Mature B-Cell Neoplasm
Plasma Cell Neoplasm

Hematologic Malignancy

Plasma Cell Neoplasm

CI-CAN-00006438Explore in graph →

HematologicNon-malignant831 active trials25 approved drugs26 evidence items

NCIt: C4665
MeSH: D054219

Overview
Statistics
Survival
Genomics2
Variants & evidence26
Drugs8
Trials3420
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (117)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 30, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 101–117 of 117 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

A Multicenter Retrospective Comparative Analysis of Therapeutic Outcomes in Multiple Myeloma Patients Receiving Varied Ixazomib Dosage Regimens.
Liang Zhao, Xiao He, Mingyang Deng et al. · Cancer Med · Sep 1, 2026 · PMID 42779200 · candidate dictionary pubmed
From toxicity to immunity: Evaluating CAR-T and conventional therapies in multiple myeloma through quality-adjusted life year (QALY) outcomes.
Guluzar Gulnur Itez, Asuman Sunguroğlu · Ther Adv Hematol · Jan 1, 2026 · PMID 42699035 · candidate dictionary pubmed
Nanomedicine-Empowered CAR-T Therapy for Multiple Myeloma: Toward Programmable, Durable, and Precision Immunotherapy.
Can Huang, Xuyan Zhang, Yuanyin Teng et al. · Int J Nanomedicine · Jan 1, 2026 · PMID 42703556 · candidate dictionary pubmed
Celiac Disease Emerging After ASCT in Multiple Myeloma: A Rare Diagnostic Intersection and Literature Review.
Mais Musleh, Mahmoud Alhamadeh Alswij, Qossay Alhusein · Case Rep Hematol · Jan 1, 2026 · PMID 42688865 · candidate dictionary pubmed
Anti-CD38 monoclonal antibodies in multiple myeloma and beyond: immunotherapeutic mechanisms, evidence maturity, and clinical positioning.
Liming Yu, Changnian Li, Dadong Guo et al. · Front Immunol · Jan 1, 2026 · PMID 42746158 · candidate dictionary pubmed
Clinical and biological significance of RAS mutations in multiple myeloma.
· Leukemia · 2008 · PMID 18528420 · validated civic_curation pubmed
Targeting the BRAF V600E mutation in multiple myeloma.

Showing 101–117 of 117 publications

← Previous
1
…
4
5
Next →

· Cancer Discov · 2013 · PMID 23612012 · validated civic_curation pubmed

NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.

· Nat Med · 2015 · PMID 26193344 · validated civic_curation pubmed

Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation.

· J Exp Clin Cancer Res · 2009 · PMID 19284554 · validated civic_curation pubmed

Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.

· Clin Lymphoma Myeloma Leuk · 2014 · PMID 24997557 · validated civic_curation pubmed

Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease.

· Br J Haematol · 2013 · PMID 23480694 · validated civic_curation pubmed

Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response.

· Oncogene · 2002 · PMID 12483530 · validated civic_curation pubmed

BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

· Cell · 2011 · PMID 21889194 · validated civic_curation pubmed

Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan.

· Blood · 2000 · PMID 11050000 · validated civic_curation pubmed

Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance.

· Blood · 2006 · PMID 16497971 · validated civic_curation pubmed

Antimyeloma activity of bromodomain inhibitors on the human myeloma cell line U266 by downregulation of MYCL.

· Anticancer Drugs · 2016 · PMID 27276402 · validated civic_curation pubmed

Lohr et al. Cancer Cell 2014

· 2014 · PMID 24434212 · validated cbioportal_study pubmed